- Document Number:
20240418706
- Appl. No:
18/335977
- Application Filed:
June 15, 2023
- نبذة مختصرة :
Disclosed are means, methods, and protocols for identifying and quantifying circulating regenerative and/or endothelial cells in a mammal in order to predict health status and risk of various pathologies. In one embodiment, determination of cardiovascular risk is performed using a blood test that assesses circulation of CD133 expressing cells, together with OCT-4 expressing cells, together with CD34/CD205 expressing cells.
- Claim:
1. A method of predicting health status in a mammal comprising the steps of: a) quantifying levels of circulating endothelial progenitor cells; b) quantifying levels of circulating regenerative cells; and c) correlating said levels of circulating endothelial progenitor cells and circulating regenerative cells with inflammatory and regenerative markers in the blood.
- Claim:
2. The method of claim 1, wherein said circulating endothelial progenitor cells express VEGF[1]receptor and c-met.
- Claim:
3. The method of claim 1, wherein said circulating endothelial progenitor cells express VEGF[1]receptor and c-met.
- Claim:
4. The method of claim 3, wherein said circulating endothelial progenitor cells multiply once every approximately 12-36 hours.
- Claim:
5. The method of claim 3, wherein said circulating endothelial progenitor cells multiply once every approximately 17-30 hours.
- Claim:
6. The method of claim 3, wherein said circulating endothelial progenitor cells multiply once every approximately 20-24 hours.
- Claim:
7. The method of claim 3, wherein said circulating endothelial progenitor cells produce interleukin 1 beta at a concentration of 1-8 picograms per million cells when stimulated with 1 ng/ml of lipopolysaccharide.
- Claim:
8. The method of claim 3, wherein said circulating endothelial progenitor cells produce interleukin 1 beta at a concentration of 5-7 picograms per million cells when stimulated with 1 ng/ml of lipopolysaccharide.
- Claim:
9. The method of claim 3, wherein said circulating endothelial progenitor cells produce at a concentration of 7 picograms per million cells when stimulated with 1 ng/ml of lipopolysaccharide.
- Claim:
10. The method of claim 3, wherein said circulating endothelial progenitor cells produce FGF[1]1 at a concentration of 9-88 picograms per million cells when stimulated with 1 ng/ml of lipopolysaccharide.
- Claim:
11. The method of claim 3, wherein said circulating endothelial progenitor cells produce interleukin 1 beta at a concentration of 30-79 picograms per million cells when stimulated with 1 ng/ml of lipopolysaccharide.
- Claim:
12. The method of claim 3, wherein said circulating endothelial progenitor cells produce interleukin 1 beta at a concentration of 40 picograms per million cells when stimulated with 1 ng/ml of lipopolysaccharide.
- Claim:
13. The method of claim 12, wherein said circulating endothelial progenitor cells express IL-3 receptor.
- Claim:
14. The method of claim 12, wherein said circulating endothelial progenitor cells express IL-5 receptor.
- Claim:
15. The method of claim 12, wherein said circulating endothelial progenitor cells express IL-8 receptor.
- Claim:
16. The method of claim 12, wherein said circulating endothelial progenitor cells express IL-10 receptor.
- Claim:
17. The method of claim 12, wherein said circulating endothelial progenitor cells express IL-13 receptor.
- Claim:
18. The method of claim 12, wherein said circulating endothelial progenitor cells express IL-17 receptor.
- Claim:
19. The method of claim 12, wherein said circulating endothelial progenitor cells express IL-21 receptor.
- Claim:
20. The method of claim 12, wherein said circulating endothelial progenitor cells express IL-33 receptor.
- Current International Class:
01
- الرقم المعرف:
edspap.20240418706
Processing Request
No Comments.